Market Place
Sourcing Support
XyloCor Therapeutics, SmartWise Enter License Agreement for Use of Extroducer
10 Jul 2024 //
CONTRACT PHARMA
XyloCor Licenses Extroducer From SmartCella For XC001 Heart Delivery
10 Jul 2024 //
PR NEWSWIRE
XyloCor`s XC001 Positive EXACT Phase 2 Data Presented, Published
02 May 2024 //
BUSINESSWIRE
XyloCor Presents Phase 2 Data Highlighting Safety and Efficacy of XC001
25 Aug 2023 //
BUSINESSWIRE
Results from XyloCor’s Phase 1 Portion of EXACT Trial of XC001 Published
03 Aug 2023 //
BUSINESSWIRE
XyloCor Reports Sustained Results of Phase 2 EXACT Clinical Trial of XC001
18 Jul 2023 //
BUSINESSWIRE
XyloCor reports positive data from refractory angina gene therapy trial
27 Jan 2023 //
CLINICAL TRIALS ARENA
XyloCor Reports Positive Safety Results from Phase 2 EXACT Trial of XC001
26 Jan 2023 //
BUSINESSWIRE
XyloCor gene therapy hits goals, paving way for pivotal trial
26 Jan 2023 //
FIERCE BIOTECH
XyloCor Achieves Target Enrollment in PII EXACT Study of XC001 Gene Therapy
28 Jun 2022 //
BUSINESSWIRE
XyloCor to Present Prelim Clinical Data from PI Portion of PI/II Study of XC001
18 May 2022 //
BUSINESSWIRE
XyloCor begins Phase II part of EXACT trial for refractory angina
28 Jul 2021 //
CLINICAL TRIAL ARENA
XyloCor Commences Phase 2 Component of Phase 1/2 EXACT Study of XC001
27 Jul 2021 //
PR NEWSWIRE
XyloCor finds new backing to push regenerative heart disease gene therapy
22 Mar 2021 //
ENDPTS
XyloCor bags $23M to expand heart disease gene therapy R&D
22 Mar 2021 //
FIERCEBIOTECH
XyloCor Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001
21 Jul 2020 //
BUSINESSWIRE
XyloCor Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001
21 Jul 2020 //
BUSINESSWIRE
XyloCor Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001
20 Jul 2020 //
MANCHESTERTIMES
XyloCor hires Reinhardt as CMO to lead gene therapy programs
07 Aug 2019 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.